Pros and cons of therapeutic drug monitoring of antiretroviral agents

被引：29

作者：

Burger, DM ^{[1
]}

Aarnoutse, RE ^{[1
]}

Hugen, PWH ^{[1
]}

机构：

[1] Univ Med Ctr Nijmegen, Dept Clin Pharm, NL-6525 GA Nijmegen, Netherlands

来源：

CURRENT OPINION IN INFECTIOUS DISEASES | 2002年 / 15卷 / 01期

关键词：

D O I：

10.1097/00001432-200202000-00004

中图分类号：

R51 [传染病];

学科分类号：

100401 ;

摘要：

Therapeutic drug monitoring has the promise to become a part of routine patient care in the treatment of HIV infection. It is known that plasma drug concentrations of protease inhibitors and non-nucleoside reverse transcriptase inhibitors are better predictors of antiviral response or toxicity than drug dose is. Furthermore, high interpatient variability is significant. In addition, therapeutic drug monitoring may be used as a direct and objective instrument to measure non-adherence. This review describes possibilities and limitations of therapeutic drug monitoring in HIV treatment. Curr Opin Infect Dis 15:17-22. (C) 2002 Lippincott Williams Wilkins.

引用

页码：17 / 22

页数：6

共 20 条

[1] Pharmacodynamics of human immunodeficiency virus type 1 protease inhibitors [J].

Acosta, EP ;

Kakuda, TN ;

Brundage, RC ;

Anderson, PL ;

Fletcher, CV .

CLINICAL INFECTIOUS DISEASES, 2000, 30 :S151-S159

[2] Indinavir plasma protein binding in HIV-1-infected adults [J].

Anderson, PL ;

Brundage, RC ;

Bushman, L ;

Kakuda, TN ;

Remmel, RP ;

Fletcher, CV .

AIDS, 2000, 14 (15) :2293-2297

[3] An argument for routine therapeutic drug monitoring of HIV-1 protease inhibitors during pregnancy [J].

Angel, JB ;

Khaliq, Y ;

Monpetit, ML ;

Cameron, DW ;

Gallicano, K .

AIDS, 2001, 15 (03) :417-419

[4] The role of therapeutic drug monitoring in treatment of HIV infection [J].

Back, DJ ;

Khoo, SH ;

Gibbons, SE ;

Merry, C .

BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 2001, 51 (04) :301-308

[5] Analysis of variation in plasma concentrations of nelfinavir and its active metabolite M8 in HIV-positive patients [J].

Baede-van Dijk, PA ;

Hugen, PWH ;

Verweij-van Wissen, CPWGM ;

Koopmans, PP ;

Burger, DM ;

Hekster, YA .

AIDS, 2001, 15 (08) :991-998

[6] Pharmacokinetics of the protease inhibitor indinavir in human immunodeficiency virus type 1-infected children [J].

Burger, DM ;

van Rossum, AMC ;

Hugen, PWH ;

Suur, MH ;

Hartwig, NG ;

Geelen, SPM ;

Scherpbier, HJ ;

Hoetelmans, RMW ;

Vulto, AG ;

de Groot, R .

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2001, 45 (03) :701-705

[7] A retrospective, cohort-based survey of patients using twice-daily indinavir plus ritonavir combinations: Pharmacokinetics, safety, and efficacy [J].

Burger, DM ;

Hugen, PWH ;

Aarnoutse, RE ;

Dieleman, JP ;

Prins, JM ;

van der Poll, T ;

ten Veen, JH ;

Mulder, JW ;

Meenhorst, PL ;

Blok, WL ;

van der Meer, JTM ;

Reiss, P ;

Lange, JMA .

JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES, 2001, 26 (03) :218-224

[8] Drug resistance and predicted virologic responses to human immunodeficiency virus type 1 protease inhibitor therapy [J].

Condra, JH ;

Petropoulos, CJ ;

Ziermann, R ;

Schleif, WA ;

Shivaprakash, M ;

Emini, EA .

JOURNAL OF INFECTIOUS DISEASES, 2000, 182 (03) :758-765

[9] Urological complaints in relation to indinavir plasma concentrations in HIV-infected patients [J].

Dieleman, JP ;

Gyssens, IC ;

van der Ende, ME ;

de Marie, S ;

Burger, DM .

AIDS, 1999, 13 (04) :473-478

[10] Value of patient self-report and plasma human immunodeficiency virus protease inhibitor level as markers of adherence to antiretroviral therapy: Relationship to virologic response [J].

Duong, M ;

Piroth, L ;

Peytavin, G ;

Forte, F ;

Kohli, E ;

Grappin, M ;

Buisson, M ;

Chavanet, P ;

Portier, H .

CLINICAL INFECTIOUS DISEASES, 2001, 33 (03) :386-392

← 1 2 →